IKBKB
IKBKB (Inhibitor of nuclear factor kappa-B kinase subunit beta) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and an oncogene driver, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Multiple myeloma, Skin cancer, Breast cancer and 2 more.
Overview
Serine kinase that plays an essential role in the NF-kappa-B signalling pathway which is activated by multiple stimuli such as inflammatory cytokines, bacterial or viral products, DNA damages or other cellular stresses. Acts as a part of the canonical IKK complex in the conventional pathway of NF-kappa-B activation. Phosphorylates inhibitors of NF-kappa-B on 2 critical serine residues.
Open Targets scores its association with cancer at 0.70 (direct and indirect evidence; datatypes literature 0.97, genetic association 0.00, somatic mutation 0.90, clinical 0.08). IntOGen calls it a driver in 1 cohort (1 activating, 0 loss-of-function), covering Plasma Cell Myeloma.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · IKBKB (Inhibitor of nuclear factor kappa-B kinase subunit beta) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and an oncogene driver, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Multiple myeloma, Skin cancer, Breast cancer and 2 more.
- 1 · What it is
IKBKB (Inhibitor of nuclear factor kappa-B kinase subunit beta) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and an oncogene driver, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Multiple myeloma, Skin cancer, Breast cancer and 2 more.
- 2 · What goes wrong in cancer
Serine kinase that plays an essential role in the NF-kappa-B signalling pathway which is activated by multiple stimuli such as inflammatory cytokines, bacterial or viral products, DNA damages or other cellular stresses.
- 3 · How drugs use it
No product in this corpus aims at IKBKB yet. Kinases are switched on by binding ATP inside the cell, so most drugs are small molecules shaped to plug that ATP pocket.
External identifiers
Sources: HGNC HGNC:5960 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt O14920 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000104365 (association with cancer (MONDO_0004992) 0.70; per-cancer scores at or above 0.5: melanoma 0.57, skin cancer 0.56, breast cancer 0.54, lung cancer 0.53 (GraphQL API, CC0)); IntOGen IKBKB (driver in 1 cohort (Act 1, LoF 0); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Serine kinase that plays an essential role in the NF-kappa-B signalling pathway which is activated by multiple stimuli such as inflammatory cytokines, bacterial or viral products, DNA damages or other cellular stresses. Acts as a part of the canonical IKK complex in the conventional pathway of NF-kappa-B activation. Phosphorylates inhibitors of NF-kappa-B on 2 critical serine residues. These modifications allow polyubiquitination of the inhibitors and subsequent degradation by the proteasome. In turn, free NF-kappa-B is translocated into the nucleus and activates the transcription of hundreds of genes involved in immune response, growth control, or protection against apoptosis. In addition to the NF-kappa-B inhibitors, phosphorylates several other components of the signalling pathway including NEMO/IKBKG, NF-kappa-B subunits RELA and NFKB1, as well as IKK-related kinases TBK1 and IKBKE. Location: Cytoplasm; Nucleus; Membrane raft (UniProt). Locus 8p11.21 (HGNC).
- Multiple myeloma: IntOGen driver in 1 cohort (PCM)
- Skin cancer: Open Targets association 0.56 with skin cancer (MONDO_0002898)
- Breast cancer: Open Targets association 0.54 with breast cancer (MONDO_0007254)
- Lung cancer: Open Targets association 0.53 with lung cancer (MONDO_0008903)
- Melanoma: Open Targets association 0.57 with melanoma (MONDO_0005105)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.12; IntOGen calls it an activating (Act) driver in 1 cohort. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"IKBKB" OR ABSTRACT:"IKBKB" OR TITLE:"inhibitor of nuclear factor kappa B kinase subunit beta" OR ABSTRACT:"inhibitor of nuclear factor kappa B kinase subunit beta" OR TITLE:"Inhibitor of nuclear factor kappa-B kinase subunit beta" OR ABSTRACT:"Inhibitor of nuclear factor kappa-B kinase subunit beta" OR TITLE:"IKK2" OR ABSTRACT:"IKK2" OR TITLE:"NFKBIKB" OR ABSTRACT:"NFKBIKB" OR TITLE:"IKK-beta" OR ABSTRACT:"IKK-beta") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about IKBKB, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetAFDN
Shares Lung cancer (all types), Skin cancer (all types), Breast cancer (all types), IntOGen.
- TargetATP2B3
Shares Lung cancer (all types), Skin cancer (all types), Breast cancer (all types), IntOGen.
- TargetPRDM16
Shares Lung cancer (all types), Skin cancer (all types), Breast cancer (all types), IntOGen.
- TargetFCRL4
Shares Lung cancer (all types), Skin cancer (all types), Breast cancer (all types), IntOGen.
- TargetMAP3K13
Shares Lung cancer (all types), Skin cancer (all types), Breast cancer (all types), Melanoma.
- TargetMRTFA
Shares Lung cancer (all types), Skin cancer (all types), Breast cancer (all types), Melanoma.
- TargetCBLB
Shares Lung cancer (all types), Skin cancer (all types), Breast cancer (all types), IntOGen.
- TargetAFF4
Shares Lung cancer (all types), Skin cancer (all types), Breast cancer (all types), IntOGen.